SAN DIEGO, July 30, 2018 /PRNewswire/ -- Omniome, Inc., developer of an innovative new DNA sequencing platform, today announced it has raised an additional $60 million with the completion of its Series B financing. The funding round was led by Decheng Capital and Hillhouse Capital Group, joined by Lam Research Capital and Nan Fung Life Sciences as well as current investors ARCH Venture Partners, Domain Associates, Biomatics Capital Partners and Altitude Life Science Ventures.
SAN DIEGO, July 27, 2018 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company’s oral, small molecule inhibitor of MNK1/2, added on to patients already receiving an FDA-approved anti-PD-1 or anti-PD-L1 checkpoint inhibitor, which may include Keytruda, Opdivo, Tecentriq, Bavencio or Im
Co-Founder & current Chief Operating Officer Sheila Gujrathi, M.D., appointed Chief Executive Officer Co-Founder & current Chief Executive Officer Faheem Hasnain becomes Executive Chairman SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio Inc. (“Gossamer Bio”), a privately held biotechnology company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet need, today announced the closing of a $230 million Series B preferred stock
Indigo Wheat™ demonstrated average yield gains of 19% in low yielding conditions and 13% across all conditions Improving upon last year’s yield gains of 16% in low yielding conditions and 8% across all conditions, 2018 reflects year-over-year improvement, validating research and development approach Boston, Massachusetts, July 10, 2018 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, has released an early view on yield d